Re-Use of Established Drugs for Anti-Metastatic Indications

Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate s...

Full description

Bibliographic Details
Main Authors: Frank Entschladen, Dane A. Thyssen, David W. Drell
Format: Article
Language:English
Published: MDPI AG 2016-01-01
Series:Cells
Subjects:
Online Access:http://www.mdpi.com/2073-4409/5/1/2
id doaj-d1dac70d67ca47148b4a527601c17a7c
record_format Article
spelling doaj-d1dac70d67ca47148b4a527601c17a7c2020-11-24T23:14:26ZengMDPI AGCells2073-44092016-01-0151210.3390/cells5010002cells5010002Re-Use of Established Drugs for Anti-Metastatic IndicationsFrank Entschladen0Dane A. Thyssen1David W. Drell2MetaVì Labs Inc., 16238 Ranch Road 620 North, Suite F-347, Austin, TX 78717, USAMetaVì Labs Inc., 16238 Ranch Road 620 North, Suite F-347, Austin, TX 78717, USAMetaVì Labs Inc., 16238 Ranch Road 620 North, Suite F-347, Austin, TX 78717, USAMost patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication.http://www.mdpi.com/2073-4409/5/1/2cancermetastasiscell migrationdrug screening
collection DOAJ
language English
format Article
sources DOAJ
author Frank Entschladen
Dane A. Thyssen
David W. Drell
spellingShingle Frank Entschladen
Dane A. Thyssen
David W. Drell
Re-Use of Established Drugs for Anti-Metastatic Indications
Cells
cancer
metastasis
cell migration
drug screening
author_facet Frank Entschladen
Dane A. Thyssen
David W. Drell
author_sort Frank Entschladen
title Re-Use of Established Drugs for Anti-Metastatic Indications
title_short Re-Use of Established Drugs for Anti-Metastatic Indications
title_full Re-Use of Established Drugs for Anti-Metastatic Indications
title_fullStr Re-Use of Established Drugs for Anti-Metastatic Indications
title_full_unstemmed Re-Use of Established Drugs for Anti-Metastatic Indications
title_sort re-use of established drugs for anti-metastatic indications
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2016-01-01
description Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication.
topic cancer
metastasis
cell migration
drug screening
url http://www.mdpi.com/2073-4409/5/1/2
work_keys_str_mv AT frankentschladen reuseofestablisheddrugsforantimetastaticindications
AT daneathyssen reuseofestablisheddrugsforantimetastaticindications
AT davidwdrell reuseofestablisheddrugsforantimetastaticindications
_version_ 1725594339530244096